Breast Cancer In Men Research Articles

Prevalence of BRCA1 and BRCA 2 and other mutations in Chilean population.

e13553 Background: Arturo López Pérez Foundation (FALP) is a Chilean Institution aimed to treatment of cancer patients. Since 2016 it has an Unit for Oncological Genetic Counseling (AGO) for patients with warning flags of potential cases of cancer of genetic origin AGO Unit is aimed to capture patients with warning flags and deliver information through pre-test counseling, offer possibility of a genetic test and post-test counseling. The purpose of this review is to provide relevant results of four years of this Unit. Methods: A descriptive study was carried out from patient care in the Oncological Genetic Counseling Unit of FALP between 2016 and 2019. It was considered those cases in which the process of pretest/post-test counseling was performed. Six "warningflags" were established: cancer in patients under 50 years of age, triple negative breast cancer, breast cancer in men, ovarian cancer, history of 2 or more primary cancers and a family history of cancer The number of test performed was analyzed. The results were expressed in positive pathogenic variants, uncertain variants and negative results. Results: 365 genetic counseling processes were carried out during the period. The average consultation age was 43.2 years (20.8 and 75.5) and 90.1% (329 attentions ) were female. Of the patients, 79.7% (294) perform the genetic test. 18.5% tested positive for a pathogenic variant, 6.5% for a pathogenic variant plus an uncertain variable, and 2.8% for two pathogenic variants. The mutations found were BRCA2 32.6% BRCA1 29.1%, ATM 10.1% RAD51C 6.7% CDKN2 A 5.6%, MUTYH 3.4% TP53 3.4%, MSH2 3.4% RAD51D 2.4%), NF1 1.1%, NTHL1 1.1%, RET 1.1% A 64.9% (237 patients) had cancer diagnosed at the time of the consultation, versus 33.1% of healthy care. 2% had no information. The type of cancer present was 79.7% breast cancer (189), 8.0% ovarian cancer, 2.1% thyroid cancer, 1.7% breast and ovarian cancer, 0.9% colon and/or endometrial cancer and 7.6% other cancers. The warning flags present were 41.2% age below 50 years, 26.2% family history, 15.4% relatives of people with positive results, 8.5% patients with triple-negative breast cancer, 5.3% patients with ovarian cancer, 2.8% patients with 2 or more primary cancers, and 0.6% male breast cancer patients. Conclusions: The highest percentage of patient care was for women with breast cancer, under 50 years of age. The overall test positivity rate is a cumulative 29%. Mutations in BRCA 1 and BRCA 2 were the most detected mutations, as reported in the literature. The slight predominance of BRCA 2 may be due to a familiar component. This is the largest report made in the Chilean population.

PROTAGONIST SURVIVOR IN TELEVISION DRAMA SCENE

This research discusses about message meaning of breast cancer in Korean Drama called Jealousy Incarnate . The concept is taken because breast cancer in men is still considered taboo in the society. Author uses Charles Sanders Peirce’s Semiotic Theory to analyze the meaning of messages in the South Korean television drama Jealousy Incarnate . The method use for this research is qualitative method. Author took data from SBS television drama, that is Wednesday and Thursday slots titles Jealousy Incarnate which the authors took from sources of indoxxi.tube, textbooks, electronic articles and publications related to the television drama Jealousy Incarnate , breast cancer, and Charles Sanders Peirce’s Semiotic Theory. The results of the analysis of this study indicate that in the Korean television drama Jealousy Incarnate there are scenes that contain messages about the protagonist survivor breast cancer in men. The drama made people aware, especially men, to be more cautious against breast cancer.

Ganglio centinela en el cáncer de mama masculino: reporte de caso y revisión de la literatura

IntroductionMale breast cancer accounts for <1% of all malignancies in men, and although it shares many similarities with breast cancer in women, it has important differences. Case reportA 68-year-old male patient presented with a 5-month history of a nodular lesion in the areolar region of the left breast accompanied by occasional pain and progressive growth. An ultrasound scan showed a heterogeneous lesion with irregular edges and calcifications, BIRADSV. It was decided to perform a mastectomy and sentinel lymph node biopsy, with positivity in the transoperative period, and axillary lymphadenectomy was completed. The histopathology report confirmed infiltrating ductal carcinoma, sentinel lymph node- and satellite-positive for metastatic carcinoma. ConclusionSeveral questions remain unanswered about breast cancer in men. It is important to enhance understanding of the biology of the disease to identify the differences between the two sexes and thus determine if they have therapeutic implications.

Epistemic Injustice in Health Care Professionals and Male Breast Cancer Patients Encounters

ABSTRACT Breast cancer affects well-being and life quality. Despite being labeled as a woman’s disease, the incidence of breast cancer in men is increasing. Men with breast cancer are diagnosed at later stages and experience stigmatization within the health care system. As such, they are prone to gender-based inequalities in health care. This paper examines epistemic injustice in health care professionals and male breast cancer patients’ encounters through analysis of research on the experiences of male breast cancer patients. Research indicates that care professionals often do not seriously consider the complaints of men with breast cancer and do not accurately interpret their symptoms.

Selbstberichtete Krebserkrankungen in der NAKO Gesundheitsstudie: Erfassungsmethoden und erste Ergebnisse

ZusammenfassungHintergrundIn der NAKO Gesundheitsstudie liegen die Daten zu selbstberichteten Krebserkrankungen der ersten Hälfte der Teilnehmenden vor.ZielBeschreibung der Methoden zur Erfassung selbstberichteter Krebserkrankungen und Tumorlokalisationen in der NAKO und Darstellung erster Ergebnisse.Material und MethodenIn einem computergestützten, standardisierten persönlichen Interview wurden 101.787 Teilnehmende (54.526 Frauen, 47.261 Männer) gefragt, ob bei ihnen jemals eine Krebserkrankung (bösartiger Tumor einschließlich in situ) ärztlich diagnostiziert wurde und wie viele Krebserkrankungen sie hatten. Anhand einer Liste wurde die Tumorlokalisation erfragt. Absolute und relative Häufigkeiten von Selbstangaben zu Krebserkrankungen insgesamt und einzelnen Tumorlokalisationen wurden berechnet und mit krebsregisterbasierten Daten verglichen.ErgebnisseEine ärztlich diagnostizierte Krebserkrankung wurde von 9,4 % der Frauen und 7,0 % der Männer berichtet. Von den Personen, die eine Krebserkrankung berichteten, gaben 88,3 % der Teilnehmenden an, nur eine Krebserkrankung gehabt zu haben. Bei Frauen war die häufigste bösartige Krebserkrankung Brustkrebs, gefolgt von Gebärmutterhalskrebs und malignem Melanom, bei Männern Prostatakrebs, gefolgt von malignem Melanom und Darmkrebs. Beim Vergleich der Krebserkrankungen, die von 45- bis 74-jährigen NAKO-Teilnehmenden in den letzten fünf Jahren berichtet wurden, mit krebsregisterbasierten 5‑Jahres-Prävalenzen wurden für die meisten Tumorlokalisationen in der NAKO niedrigere relative Häufigkeiten beobachtet. Vergleichsweise häufiger traten das maligne Melanom sowie Gebärmutterhalskrebs und Leberkrebs bei Frauen und Harnblasenkrebs und Brustkrebs bei Männern auf.DiskussionDie NAKO ist eine reichhaltige Datenbasis für die zukünftige Untersuchung inzidenter Krebserkrankungen.

Abstract P4-07-05: Matched germline and tumor profiling in male breast cancer for the discovery of molecular subtypes with clinical relevance

Abstract Background: Breast cancer (BC) in men is a rare disease, but morbidity and mortality in male BC (MBC) patients is a serious concern. Because of its rarity, to date, clinical management of men with BC has been informed almost entirely by female BC research. However, BC in men and women may behave differently. Inherited mutations in homologous recombination (HR) genes, mainly BRCA1,BRCA2 and PALB2, play a major role in MBC predisposition. MBCs associated with mutations in HR gene are likely to represent a subgroup of tumors with a peculiar tumor phenotype. Here, we performed a transcriptome analysis of MBCs characterized for germline mutations in HR genes in order to provide insight into underlying HR pathways and characterize distinct molecular subtypes of MBC with possible clinical relevance. Materials and methods: MBC cases were selected to include cases with and without germline mutations in HR genes. Tumor samples with pathology and outcome data were selected within the Italian multicenter study on MBC that comprises 750 MBCs with information on germline mutations in 50 cancer-related genes. To enrich the series of MBC cases with germline mutations in HR genes, tumor samples from kConFab were also included. Overall, 63 tumor samples, including 26 cases with germline mutations in HR genes (BRCA2, BRCA1, PALB2, RAD50 and RAD51D) and 37 without germline mutations, were analyzed. Whole transcriptome data were obtained by RNA-sequencing using Illumina technology. A bioinformatic pipeline including FastQC tool for quality control, STAR for alignment, RSeQC-FPKM for counting reads, DESeq2 package for differential expression and DAVID for enrichment, was used. Tumor immunophenotype was evaluated using CIBERSORT, which accurately determines the fraction of 22 immune cell types. Statistical analyses were performed using Fisher exact test, t-test and log-rank test as appropriate. Results: A total of 724 differentially expressed genes, of which 355 up-regulated and 369 down-regulated, emerged between MBC cases with and without germline mutations in HR genes. Pathway-based analyses revealed different transcriptome profiles for genes involved in key biological processes, including translational initiation, cell cycle, DNA damage and repair. A higher fraction of activated CD4 memory T cells was observed in tumors with germline mutations in HR genes compared to those without mutations (p=0.04). Unsupervised clustering approach, based on the 2000 most variable transcripts among tumors, revealed two distinct subgroups with different biologic features and clinical outcome. In particular, tumors in subgroup 1 showed higher expression of genes involved in cell proliferation, were enriched for cases with germline mutations in HR genes (p=0.03), had lymph node involvement (p=0.04) and displayed a trend toward worse overall survival (p=0.09), when compared to tumors in subgroup 2. Conclusions: Integration of matched germline and tumor profiling seem to be a valuable approach for the identification of biologically and clinically relevant subtypes of MBC. Germline mutations in HR genes could impact on MBC transcriptome, defining molecular subgroups with peculiar biological features. Overall, these results may help to improve the clinical managements of MBC patients. Study supported by AIRC (IG 21389) to L.O. Citation Format: Veronica Zelli, Valentina Silvestri, Virginia Valentini, Agostino Bucalo, Piera Rizzolo, Ines Zanna, Laura Cortesi, Daniele Calistri, Maria Grazia Tibiletti, Giuseppe Giannini, Stephen B Fox, Domenico Palli, Laura Ottini. Matched germline and tumor profiling in male breast cancer for the discovery of molecular subtypes with clinical relevance [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-07-05.

Abstract P4-17-01: Genomic profiling of primary and metastatic breast cancer in men

Abstract Background: Male breast cancer is rare, with approximately 2,600 cases diagnosed annually in the United States. Data are scant regarding the genomics and pathophysiology of male breast cancer, especially in the metastatic setting, requiring most treatment recommendations in male breast cancer to be made by inference from breast cancer in women. Methods: We performed prospective genomic profiling of primary and metastatic tumor samples from men with breast cancer treated at Memorial Sloan Kettering Cancer Center using the MSK-IMPACT targeted-DNA-sequencing panel for somatic mutations. Comprehensive demographic, clinical, and pathologic data were collected on all included patients. Statistics are descriptive. Results: Genomic sequencing was performed on 45 samples from 41 men (31 primary samples and 14 from metastatic sites). Median age at time of sample collection was 61 years, with a range of 27-92 years. Thirty-seven (90.2%) men had ER+/HER2- breast cancer, 3 (7.3%) had ER+/HER2+ breast cancer and 1 (2.4%) had triple negative disease. Thirty-nine (95.1%) had ductal carcinoma, and no cases of lobular carcinoma were identified. Forty patients underwent germline testing, and 12 (30%) were found to have pathogenic germline mutations (6 BRCA2 mutations, 2 BRCA1 mutations [one of whom had a concurrent CHEK2 mutation], and one mutation each in PALB2, MUTYH, and MSH6). Overall, the pattern of genomic alterations in male breast cancer was similar that in women. Twelve (29.3%) patients had PIK3CA mutations, 9 (22%) had GATA3 mutations, 3 (7.3%) had TP53 mutations, 3 (7.3%) had ARID1A mutations, 3 (7.3%) had KMT2C mutations, 2 (4.9%) had FOX1A mutations, 2 (4.9%) had RB1 mutations, and 2 (4.9%) had TERT promoter hotspot mutations. Eleven (26.8%) patients had CCND1 amplification, 8 (19.5%) had MYC amplification, 6 (14.6%) had FGFR1 amplification, and 5 (12.2%) had MDM2 amplification. All other findings were present in ≤ 1 patient. All included patients had normal mutational burden, and all samples were microsatellite stable. PIK3CA mutations occurred in 33% of primary samples vs. 15% of metastatic samples, CCND1 amplification occurred in 23% of primary samples vs. 38% of metastatic samples, and TERT hotspot promoter mutations were found only in metastatic samples. Of note, we observed a single ESR1 D538G mutation in the metastatic sample of a patient with significant prior exposure to aromatase inhibitors in the adjuvant and metastatic settings. We further found concurrent ERBB2 mutation and amplification in the post-treatment metastatic samples of an ER+/HER2- patient, who was treated with neratinib for 14 weeks with clinical response. Lastly, we report a heavily pretreated patient with metastatic secretory breast carcinoma who was found to have an ETV6-NTRK3 fusion gene. This patient was treated with a first-generation TRK inhibitor and continues to exhibit an ongoing clinical response at 8.6 months. Conclusions: Based on our data, the overall genomic landscape of male breast cancer appears comparable to that of breast cancer in women, as has been previously reported. However, despite the small number of metastatic cases examined, several previously unreported and treatment-informing signatures were discovered, especially in those patients with less common male breast cancer variants. Further study is warranted to confirm these findings in a larger cohort. Citation Format: Joshua Z Drago, Cristian Serna-Tamayo, Carlos H Dos Anjos, David N Brown, Shanu Modi, Komal Jhaveri, David B Solit, Tiffany A Traina, Sarat Chandarlapaty, Jorge S Reis-Filho, Mark E Robson, Ayca Gucalp, Pedram Razavi. Genomic profiling of primary and metastatic breast cancer in men [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-17-01.

Male Breast Cancer – A Review of Diagnosis And Management over 10 Years in a District General Hospital Khalid Amin, Ben Passey-Heaton, Chandeena Roshanlall. Macclesfield District General Hospital,U.K.

Background: Breast cancer in men is a rare disease. Less than 1% of all breast cancers occur in men. For men, the lifetime risk of being diagnosed with breast cancer is approximately 1: 1000. The average age of men diagnosed with breast cancer is about 68. Approximately 390 men are diagnosed with breast cancer each year in the UK, compared to around 54,800 new breast cancer diagnoses in women. Male breast cancer is managed similarly to female breast cancer due to paucity of male breast cancer specific research.

Testing brca or multigenic panels after medical recommendation

Introduction: Hereditary breast cancer represents about 10% of breast cancer cases. Risk factors for hereditary breast cancer are family history of breast cancer, ovarian cancer, breast cancer in men, among others, especially at an early age and bilateral tumors. Several hereditary syndromes have been described in relation to breast cancer, the most frequent being the Breast, Ovarian and Pancreatic Cancer Syndrome, determined by mutations in the BRCA 1 and 2 genes. In Brazil, the difficulty of accessing the genetic test of the public and private systems is still a reality, mainly due to elevate costs. Objectives: To raise patients' adherence to perform the BRCA test or multigene panels after medical recommendation at a private clinic in Piauí. Method: This is a retrospective study, evaluating medical records of patients seen in the period from 1999 to 2019. This study included all patients who had a recommendation to perform the BRCA mutation research or multigene panels. The study was approved by the ethics and research committee of Universidade Federal do Piauí, Opinion n. 2.817.502. Results: 164 patients who had a recommendation for genetic testing were studied. There were 162 female patients (98.7%) and mean age was 48.3 years. As for the presence of cancer, breast cancer was the most frequent one with 82 (79.6%) cases; as for survival, 5 (3.0%) of the cases evolved to death. 86 (52.4%) of the patients underwent the test, with mean gap between the recommendation and the test itself of 2.3 years. Of those who performed the tests, 23 (26.7%) had mutations in the BRCA gene, 15 (65.2%) in BRCA1, and 8 (34.8%) in BRCA2. Conclusions: 52.4% of the patients recommended for genetic testing performed the research. Of those who performed the tests, 26.7% had mutations in the BRCA gene, 65.2% in BRCA1, and 34.8% in BRCA2.

Breast cancer in men: a serie of 45 cases and literature review.

Immunohistochemical profiling studies carried out on female breast cancer has been extrapolated to breast cancer in males. Although, we do not know if it really reflects the reality of this pathology in males patients since the studies are often retrospective and studying a limited number of patients. The objectives was to describe particualrities of breast cancer in males and analyze the evolutionary characteristics and study the molecular profile of this rare disease in Tunisian men. It is a retrospective, descriptive and analytic study carried out over a period of 15 years in the departments of gynecology-obstetrics, general surgery, medical carcinology and anatomopathology of the Farhat Hached Teaching Hospital in Sousse, Tunisia. Fourty five patients were included.The most common histological type was invasive ductal carcinoma (95% of our patients). Our series was divided into 3 immunohistochemical groups with a majority group: luminal A (68.2%), followed by luminal B (27.3%) and only one patient had a triple negative type tumor (4.5%).The Overall survival rate (OSR) at 5 and 10 years was 83.2% and 76.8% respectively. Recurrence-free survival (RFS) at 5 and 10 years was 64.5% and 58.6%, respectively. The OSR was influenced significantly by age, clinical and histological size of the tumor, the presence of distant metastases and the occurrence of recurrence. Recurrence-free survival (RFS) was influenced by age, clinical and histological size of the tumor, and infiltration of the dermis. Breast cancer in males has similarities with women's breast cancer. However, it remains diagnosed at a later stage.

Breast Cancer May Be Biologically Different in Men Than in Women

The approach to treating breast cancer in men is largely the same as in women. However, large studies of treatments for men have been hard to come by,

Mammography Beneficial for Breast Cancer in Men

Whether screening men at high risk for breast cancer is worthwhile remains unclear. A retrospective study in these men found that mammography identified tumors when they were smaller and at an earlier stage in men who received screening than in those who received diagnostic exams.

FDA Addresses Breast Cancer in Men

Research on breast cancer is rapidly progressing, leading to new therapies and treatment approaches, yet in men with the disease it continues to lag. Recently, the FDA released a draft guidance to address this disparity, outlining strategies to improve drug development for men such as including them in clinical trials and using nontraditional data sources.

Breast Cancer in Men - Health Care Professionals' Perspectives on the Multidisciplinary Care of a Rare Disease

Male breast cancer is a rare disease, for which, however, available care is from highly specialized care structures intended for female patients. So far, it is unknown whether the focus of care structures for women leads to deficits in the care for men. Therefore, the aim of the present study was to identify possible deficits in male breast cancer care from the perspective of the health care professions involved. Semi-structured interviews with n=23 participants and 2 focus group discussions with n=7 and n=9 participants were conducted. The transcripts of the interviews and focus group discussions were analyzed by qualitative content analysis using MAXQDA. Some participants felt insecure and uniformed in terms of treatment recommendations for men with breast cancer. Often, responsibilities were vague or unknown. Many participants felt a lack of interdisciplinary cooperation, especially in follow-up care. Some respondents complained of a lack of rehabilitation centers for men with breast cancer. Male breast cancer patients benefit from the advanced structures for breast cancer care. However, some health care problems were identified. Our results together with representative data can help develop practical recommendations for improving the quality of care of male breast cancer patients.

A Review of Triple Negtive Marker of IHC in Medullary Carcinoma Breast

Medullary carcinoma of the breast is an uncommon variant of invasive ductal carcinoma, which constitutes nearly 5% of all breast cancers in men and women. These tumours are often associated with favourable prognosis despite showing aggressive behaviour. In this study a patient presented with history of breast lump aged 48 years in left breast since one year .In mammography it was described as BIRADS II and fine needle aspiration cytology showed suspicious for malignancy .Histopathology report showed medullary carcinoma breast lesion. Immunochemistry was also done for ER , PR and Her-2neu and it showed negative for ER ,PR and HER 2 Neu.

Overall Mortality After Diagnosis of Breast Cancer in Men vs Women

Survival differences between male and female patients with breast cancer have been reported, but the underlying factors associated with the disparity have not been fully studied. This understanding is fundamental to developing strategies for cancer treatment and survivorship care. To compare mortality between male and female patients with breast cancer and quantitatively evaluate the factors associated with sex-based disparity in mortality. This large, nationwide, registry-based cohort study used the National Cancer Database to identify and obtain data on patients who received a breast cancer diagnosis between January 1, 2004, and December 31, 2014. After exclusions, the final study population comprised 1 816 733 patients. Statistical analyses were conducted from September 1, 2018, to January 15, 2019. The primary outcome was overall survival. Secondary outcomes were 3-year and 5-year mortality. Mortality differences were evaluated by Kaplan-Meier analysis. The roles of race/ethnicity, clinical characteristics, treatments, and access-to-care factors in the association between sex and mortality were estimated by nested Cox proportional hazards regression models with adjustment for age. In total, 16 025 male (mean [SD] age, 63.3 [13.0] years) and 1 800 708 female (mean [SD] age, 59.9 [13.3] years) patients with breast cancer were included in the study. Compared with female patients, male patients had higher mortality across all stages. For men, the overall survival rate was 45.8% (95% CI, 49.5-54.0; P < .001), the 3-year rate was 86.4% (95% CI, 85.9-87.0; P < .001), and the 5-year rate was 77.6% (95% CI, 76.8-78.3; P < .001). For women, the overall survival rate was 60.4% (95% CI, 58.7-62.0; P < .001), the 3-year rate was 91.7% (95% CI, 91.7-91.8; P < .001), and the 5-year rate was 86.4% (95% CI, 86.4-86.5; P < .001). Overall, clinical characteristics and undertreatments were associated with a 63.3% excess mortality rate for male patients. A higher proportion of excess deaths in men were explained by these factors in the first 3 years after breast cancer diagnosis (66.0%) and in all patients with early-stage cancer (30.5% for stage I and 13.6% for stage II). However, sex remained a significant factor associated with overall mortality (adjusted hazard ratio [HR], 1.19; 95% CI, 1.16-1.23) as well as mortality at 3-year (adjusted HR, 1.15; 95% CI, 1.10-1.21) and 5-year (adjusted HR, 1.19; 95% CI, 1.14-1.23) analyses, even after adjustment for clinical characteristics, treatment factors, age, race/ethnicity, and access to care. This study found that mortality after cancer diagnosis was higher among male patients with breast cancer compared with their female counterparts. Such disparity appeared to persist after accounting for clinical characteristics, treatment factors, and access to care, suggesting that other factors (particularly additional biological attributes, treatment compliance, and lifestyle factors) should be identified to help in eliminating this disparity.

Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk.

Breast cancer in men is a rare and still poorly characterized disease. Inherited mutations in BRCA1, BRCA2 and PALB2 genes, as well as common polymorphisms, play a role in male breast cancer genetic predisposition. Male breast cancer is considered a hormone-dependent tumor specifically related to hyperestrogenism. Polymorphisms in genes involved in estrogen biosynthesis and metabolism pathways, such as CYP17A1 and CYP1B1, have been associated with breast cancer risk. Here, we aimed to investigate the role of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. A series of 597 male breast cancer cases and 1022 male controls, recruited within the Italian Multicenter Study on male breast cancer, was genotyped for CYP17A1 rs743572, CYP1B1 rs1056836 and rs1800440 polymorphisms by allelic discrimination real-time PCR with TaqMan probes. Associations with male breast cancer risk were estimated using logistic regression. No statistically significant associations between male breast cancer risk and the three analyzed polymorphisms emerged. Similar results were obtained also when BRCA1/2 mutational status was considered. No significant differences in the distribution of the genotypes according to estrogen receptor status emerged. In conclusion, our study, based on a large series of male breast cancer cases, is likely to exclude a relevant role of CYP17A1 and CYP1B1 polymorphisms in male breast cancer predisposition. Overall, these results add new data to the increasing evidence that polymorphisms in these genes may not be associated with breast cancer risk.

Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET).

1055 Background: The rarity of BC in men limits the feasibility of randomized clinical studies in this population. Treatment guidelines recommend that men with BC be treated similarly to postmenopausal women. PAL, a cyclin-dependent kinase 4/6 inhibitor, is used in men with metastatic BC (mBC) in real-world clinical practice, presenting an opportunity to utilize real-world evidence to enable healthcare providers to assess novel agents in this space. Methods: Two parallel approaches were taken. In the first approach, pharmacy and medical claims data from IQVIA Inc were retrospectively analyzed to describe the treatment patterns and duration of PAL + ET (aromatase inhibitor or fulvestrant) compared to ET in men with mBC. The second approach was a retrospective analysis of data derived from electronic health records in the Flatiron Health database to understand real-world clinical response to PAL + ET vs ET alone. Median duration of treatment (mDOT) was estimated by the Kaplan-Meier method. Results: Between Feb 2015 and Apr 2017, 12.9% (147/1139 [IQVIA dataset]) of men receiving treatment for mBC were prescribed PAL + ET for any line of therapy. The mDOT in the first-line setting was numerically longer in the PAL cohort (n=37) compared with the non-PAL cohort (n=214; 8.5 vs 4.3 mo, respectively). In particular, mDOT in the first-line setting was longer with PAL + letrozole (LET; n=26) than with LET alone (n=63; 9.4 vs 3.0 mo, respectively). In the Flatiron Health dataset between Feb 2015 and July 2017, the real-world maximum response rate in the PAL + ET cohort across all lines of therapy in the mBC setting (n=12) was 33.3% (2 complete responses [CR], 2 partial responses [PR]) vs 12.5% (0 CR, 1 PR) for the ET alone cohort (n=8). Conclusions: The real-world data sources used in this study support that men with mBC derive clinical benefit from the addition of PAL to ET. Given the challenges of conducting randomized clinical trials in men with mBC, noninterventional, real-world evidence data appear to be useful to delineate the benefit of such therapies in this setting. Funding: Pfizer.

FMTVDM/BEST Imaging Equally Applicable for Male Breast Cancer

Prior to FMTVDM/BEST Imaging, diagnostic testing was limited to looking for breast cancer either using 'qualitative' imaging defining disease as either present or absent, or semiquantitative methods which is also limited to the same yes you have breast cancer or no you don’t interpretation. These imaging methods include mammography, ultrasound, CT, MRI, as well as other SPECT/Planar and PET imaging approaches and as such are associated with sensitivity and specificity problems. These tests are further limited when imaging dense breast tissue or when breast implants exist either for augmentation, following mastectomy or when looking for breast cancer in men.

P084 - Breast cancer in men: 10-year experience of an Oncology Reference Center in Northeast Mexico

P084 - Breast cancer in men: 10-year experience of an Oncology Reference Center in Northeast Mexico